Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer: A biomarker-stratified randomized phase II trial

Journal of Clinical Oncology

Volumn 33, Issue 22, 2015, Pages 2450-2456

  Sun, Jong Mu ^a   Ahn, Jin Seok ^a   Jung, Sin Ho ^a,b   Sun, Jiyu ^a   Ha, Sang Yun ^a   Han, Joungho ^a   Park, Keunchil ^a   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; GLUTAMIC ACID DERIVATIVE; GUANINE; TUMOR MARKER;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84940397966     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.9324     Document Type: Article

References (21)

1. National Comprehensive Cancer Network: NCCN Clinical Practice Guideline in Oncology: Non-Small Cell Lung Cancer, Version 4. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
2. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
3. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
4. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
5. Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107:1589-1596, 2006
6. Sun JM, Han J, Ahn JS, et al: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small-cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6:1392-1399, 2011
7. Tanaka F, Wada H, Fukui Y, et al: Thymidylate synthase (TS) gene expression in primary lung cancer patients: A large-scale study in Japanese population. Ann Oncol 22:1791-1797, 2011
8. Ozasa H, Oguri T, Uemura T, et al: Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101:161-166, 2010
9. Hashimoto H, Ozeki Y, Sato M, et al: Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 106:1595-1601, 2006
10. Chen CY, Chang YL, Shih JY, et al: Thymidylate synthase and dihydrofolate reductase expression in non-small-cell lung carcinoma: The association with treatment efficacy of pemetrexed. Lung Cancer 74:132-138, 2011
11. Christoph DC, Asuncion BR, Hassan B, et al: Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 8:19-30, 2013
12. Nicolson MC, Fennell DA, Ferry D, et al: Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 8:930-939, 2013
13. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
14. Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol 25:5233-5239, 2007
15. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
16. Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247-255, 2012
17. Nakagawa T, Otake Y, Yanagihara K, et al: Expression of thymidylate synthase is correlated with proliferative activity in non-small-cell lung cancer (NSCLC). Lung Cancer 43:145-149, 2004
18. Faneyte IF, Schrama JG, Peterse JL, et al: Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 88:406-412, 2003
19. Archer CD, Parton M, Smith IE, et al: Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89:1035-1041, 2003
20. Gronberg BH, Lund-Iversen M, Strom EH, et al: Associations between TS, TTF-1, FR-alpha, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol 8:1255-1264, 2013
21. Shintani Y, Ohta M, Hirabayashi H, et al: New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 104:790-795, 2003